Categorynews

Exelixis Announces Webcasts of Investor Conference Presentations in June 2019

May 29, 2019 Off By BusinessWire

̶ Presentations to be webcast on www.exelixis.com
̶

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be
presenting at the following three investor conferences in June 2019:

William Blair 39^th Annual Growth Stock Conference: Exelixis
is scheduled to present at 5:00 PM EDT / 2:00 PM PDT on Wednesday,
June 5, 2019 in Chicago.
Goldman Sachs 40^th Annual Global Healthcare Conference:
Exelixis is scheduled to present at 11:40 AM EDT / 8:40 AM PDT on
Wednesday, June 12, 2019 in Rancho Palos Verdes, CA.
BMO Capital Markets Prescription for Success Healthcare Conference:
Exelixis is scheduled to present at 8:00 AM EDT / 5:00 AM PDT on
Tuesday, June 25, 2019 in New York.

To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the Investors &
Media heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days
following each presentation.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. Our discovery efforts
have resulted in four commercially available products, CABOMETYX^® (cabozantinib),
COMETRIQ^®(cabozantinib), COTELLIC^®(cobimetinib)
and MINNEBRO^® (esaxerenone), and we have entered into
partnerships with leading pharmaceutical companies to bring these
important medicines to patients worldwide. Supported by revenues from
our marketed products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our pipeline.
We are supplementing our existing therapeutic assets with targeted
business development activities and internal drug discovery — all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis is a member of the Standard &
Poor’s (S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information about Exelixis,
please visit www.exelixis.com,
follow @ExelixisInc on
Twitter or like Exelixis,
Inc. on Facebook.